Evaluation of the preventive effect of bisoprolol fumarate on postoperative hypertension and atrial fibrillation in in eldery patient on acute and chronic phase.

Evaluation of the preventive effect of bisoprolol fumarate on postoperative hypertension and atrial fibrillation in in eldery patient on acute and chronic phase. - EBAF study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004600

Enrollment

100

Registered

2010-12-01

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative atrial fibrillation

Interventions

Administration bisoprolol fumarate (initial dose is 2.5mg) Conventional care without administration of bisoprolol fumarate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: all elective cases in our department (cardiac and aortic surgery)

Exclusion criteria

Exclusion criteria: patients on beta-blocker preoperatively patients with likelihood for ostoperative beta-blocker therapy co-morbid bronchial asthma (FEV1.0 less than 1000ml) co-morbid diabetes mellitus (HbA1c more than 8 percent) persistent atrial fibrillation before entering ICU the case already implanted permanent pacemaker allergic to bisoprolol fumarate

Design outcomes

Primary

Measure	Time frame
Occurrence of postoperative atrial fibrillation	—

Secondary

Measure	Time frame
the activated level of sympathetic nerve(Holter ECG) cardiovascular event level of inflammatory biomarker	—

Countries

Japan

Contacts

Public ContactYoshikatsu Saiki

Tohoku University Hospotal Cardiovascular Surgery

022-717-7222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026